- Home
- EVN vs CERS Comparison
EVN vs CERS Comparison
Compare EVN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- CERS
- Stock Information
- Founded
- EVN 1998
- CERS 1991
- Country
- EVN United States
- CERS United States
- Employees
- EVN N/A
- CERS N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- CERS EDP Services
- Sector
- EVN Finance
- CERS Technology
- Exchange
- EVN Nasdaq
- CERS Nasdaq
- Market Cap
- EVN 410.0M
- CERS 347.3M
- IPO Year
- EVN N/A
- CERS 1997
- Fundamental
- Price
- EVN $10.35
- CERS $1.38
- Analyst Decision
- EVN
- CERS Strong Buy
- Analyst Count
- EVN 0
- CERS 2
- Target Price
- EVN N/A
- CERS $3.50
- AVG Volume (30 Days)
- EVN 101.2K
- CERS 1.5M
- Earning Date
- EVN 01-01-0001
- CERS 05-01-2025
- Dividend Yield
- EVN 4.78%
- CERS N/A
- EPS Growth
- EVN N/A
- CERS N/A
- EPS
- EVN 0.34
- CERS N/A
- Revenue
- EVN N/A
- CERS $180,270,000.00
- Revenue This Year
- EVN N/A
- CERS $25.22
- Revenue Next Year
- EVN N/A
- CERS $10.08
- P/E Ratio
- EVN $29.94
- CERS N/A
- Revenue Growth
- EVN N/A
- CERS 15.29
- 52 Week Low
- EVN $8.64
- CERS $1.34
- 52 Week High
- EVN $10.45
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- EVN 44.77
- CERS 35.86
- Support Level
- EVN $10.18
- CERS $1.40
- Resistance Level
- EVN $10.69
- CERS $1.58
- Average True Range (ATR)
- EVN 0.14
- CERS 0.08
- MACD
- EVN -0.02
- CERS -0.00
- Stochastic Oscillator
- EVN 32.35
- CERS 16.00
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.